Ascorbic acid 2-phosphate-releasing poly-l-lactide-co-epsilon-caprolactone membranes enhance tissue regeneration: first <i>in vivo</i> insights for pelvic organ prolapse
Kurki A., Hannula M., Miettinen S., Teittinen H., Paakinaho K., Hyttinen J.
Animal Study, published in Regen Biomater (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Regen Biomater (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41287757
- PMCID
- PMC12640511
- DOI
- 10.1093/rb/rbaf097
- Citations
- 2
Abstract (original English)
Pelvic organ prolapse (POP) significantly impacts women's health and quality of life. There is a critical need for alternative biomaterials for surgical POP repair, driven by complications associated with conventional non-absorbable vaginal meshes. As ascorbic acid 2-phosphate (A2P) has been demonstrated to enhance collagen production and cell proliferation in vitro , this study investigated absorbable A2P-releasing poly-l-lactide-co-epsilon-caprolactone (PLCL) membranes in the first in vivo study to evaluate their potential to promote tissue regeneration for POP treatment. Biomaterials (PLCL, PLCL 4%A2P , PLCL 8%A2P and commercial polypropylene (PP) mesh) were implanted subcutaneously on the abdominal fascia of female Sprague-Dawley rats, and tissue samples were collected for tensile testing and histological analysis at 1-week, 1-month and 6-month time points. Histological samples were analysed using X-ray micro-computed tomography, histological stains, and primary antibodies targeting type I and type III collagen to assess connective tissue regeneration and material degradation. The PLCL A2P groups demonstrated enhanced tissue strength without increased stiffness, compensating for material degradation through tissue regeneration. Moreover, collagen amount was increased in the PLCL 4%A2P and PLCL 8%A2P groups, without signs of adverse fibrosis. Our results suggest that A2P-rel
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.